

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/591,743
				<i>Filing Date</i>	Unassigned
				<i>First Named Inventor</i>	Alley, Stephen C.
				<i>Art Unit</i>	Unassigned
				<i>Examiner Name</i>	Unassigned
(Use as many sheets as necessary)				<i>Attorney Docket Number</i>	018891-000720US
Sheet	2	of	3		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	16	DORAL et al., "Role of Inter-Heavy and Light Chain Disulfide Bonds in the Effector Functions of Human Immunoglobulin IgG1," <i>Molecular Immunology</i> , 29(12):1487-1491 (1992).	<input type="checkbox"/>		
	17	FRANCISCO et al., "cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity," <i>Blood</i> , 102(4):1458-1465 (August 15, 2003).	<input type="checkbox"/>		
	18	GILLIES et al., "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," <i>Hum. Antibod. Hybridomas</i> , 1(1):47-54 (1990).	<input type="checkbox"/>		
	19	HAMANN et al., "Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody-Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia," <i>Bioconjugate Chem.</i> , 13:47-58 (2002).	<input type="checkbox"/>		
	20	International Search Report of 8/17/2006 for International Application PCT/US05/07239.	<input type="checkbox"/>		
	21	LYONS et al., "Site-specific attachment to recombinant antibodies via introduced surface cysteine residues," <i>Prot. Eng.</i> , 3(8):703-708 (1990).	<input type="checkbox"/>		
	22	OI et al., "Chimeric Antibodies," <i>BioTechniques</i> , 4(3):214-221 (1986).	<input type="checkbox"/>		
	23	Product description of Mylotarg® (gemtuzumab ozogamicin for Injection), by Wyeth Pharmaceuticals, Inc., 7/04 revision, pages 1-19.	<input type="checkbox"/>		
	24	QU et al., "Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates," <i>J. Immunological Methods</i> , 213:131-144 (1998).	<input type="checkbox"/>		
	25	RODWELL et al., "Site-specific covalent modification of monoclonal antibodies: <i>In vitro</i> and <i>in vivo</i> evaluations," <i>PNAS</i> , 83:2632-2636 (April 1986).	<input type="checkbox"/>		
	26	SAITO et al., "Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities," <i>Advanced Drug Delivery Reviews</i> , 55:199-215 (2003).	<input type="checkbox"/>		
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number

10/591,743

Filing Date

Unassigned

First Named Inventor

Alley, Stephen C.

Art Unit

Unassigned

Examiner Name

Unassigned

Attorney Docket Number

018891-000720US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	27	STIMMEL et al., "Site-specific Conjugation on Serine -> Cysteine Variant Monoclonal Antibodies," <u>J. Biol. Chem.</u> , 275(39):30445-30450 (2000).	<input type="checkbox"/>
	28	SUN et al., "Reduction-Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides," <u>Bioconjugate Chem.</u> , 16:1282-1290 (2005).	<input type="checkbox"/>
	29	Written Opinion of 8/17/06 for International Application PCT/US05/07239.	<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.